Day: March 4, 2021

– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 –– On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease in mid-2021 –– Company to discontinue Phase 3 COVID-19 trial (LOSVID) –– Extended cash runway into 4Q 2022; raised $50.6 million in gross proceeds from January 2021 public offering –– Conference call scheduled for 8:00 a.m. ET today –CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2020.“In 2020, we made...

Electric and Hybrid Vehicle Application GrowthStrong Free Cash FlowSignificant Debt ReductionCHICAGO, March 04, 2021 (GLOBE NEWSWIRE) — Methode Electronics, Inc. (NYSE: MEI), a global developer of custom engineered and application specific products and solutions, today announced financial results for the fiscal third quarter of 2021 ended January 30, 2021.For the fiscal third quarter ended January 30, 2021, the company’s accounting period included 13 weeks compared to 14 weeks for the fiscal third quarter ended February 1, 2020. The following discussions of comparative results between these two periods should be reviewed in this context.Fiscal Third Quarter 2021 HighlightsNet sales were $295.3 millionElectric and hybrid vehicle applications were over 12 percent of net salesNet income was $31.9 million, or $0.83 per diluted...

OTTAWA, March 04, 2021 (GLOBE NEWSWIRE) — Telesat today announced its financial results for the three-month and one-year periods ended December 31, 2020. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (“IFRS”) unless otherwise noted.For the year ended December 31, 2020, Telesat reported consolidated revenue of $820 million, a decrease of 10% ($90 million) compared to the same period in 2019. When adjusted for changes in foreign exchange rates, revenue decreased 10% ($87 million) compared to 2019. The revenue decrease was due to lower short-term services provided to other satellite operators, a reduction of service for a broadcast customer, the completion of the non-cash amortization of a significant financing component of an agreement, and the impact of the COVID-19 pandemic, particularly...

Strong execution in 2020 sets stage for advancing five clinical programs and novel ADAR editing modality in 2021Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease on track for end of 1Q 2021Moving towards first patient dosing in three clinical trials with pipeline candidates incorporating PN chemistry: WVE-003 (SNP3), WVE-004 (C9orf72) and WVE-N531 (Exon 53)Cash runway expected into 2Q 2023Wave to host investor conference call and webcast at 8:00 a.m. ET todayCAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.“Wave...

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.“We continue to make progress in the trial and utilization of our two commercially launched products, driving market share in the acne and rosacea categories,” said David Domzalski, Chief Executive Officer of VYNE. “Our R&D team has made significant strides in developing our investigational product pipeline, having successfully advanced FCD105, our minocycline-adapalene combination product candidate for moderate-to-severe acne, which we anticipate commencing a Phase 3 program later this year. Additionally, we are excited about the pre-clinical data and prospects of our newest candidate FMX114,...

(all amounts expressed in US dollars)TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — SRHI Inc. (“SRHI” or the “Company” – formerly Sprott Resource Holdings Inc.) today announced its operating and financial results for the year ended December 31, 2020. The Company’s principal operating business is its 70% owned producing copper mine Minera Tres Valles SpA (“MTV“) in Salamanca, Chile. The Company’s financial statements and management’s discussion and analysis (“MD&A“) are available at www.srhi.ca and www.sedar.com.MTV restarts operations at its open pit, Don GabrielConstruction and development of its incline block caving mine at its Papomono Masivo deposit (“Papomono Masivo“) remains on schedule and on budget to be in commercial production by early 2022The...

– $115.1 million follow-on financing completed in February 2021– First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021– $16.5 million monetization of ILUVIEN Royalty with $15 million applied to reduction in debt obligations in December 2020– $15.7 million equity investment by Asia partner Ocumension Therapeutics in December 2020– Total revenues for Full Year 2020 of $34.4 million including net product revenues of $20.8 million – Management to host a conference call and webcast today at 8:30 AM ET WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced financial results...

LONDON, March 04, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the fourth quarter and full year ended December 31, 2020.“Autolus’ primary focus is on delivering the potential pivotal AUTO1 program and the company starts 2021 in a position of financial strength, having raised a total of $131 million in gross proceeds this quarter, giving us a cash runway into the first half of 2023,” said Dr. Christian Itin, chairman and chief executive officer of Autolus. “We are excited about the unique characteristics of AUTO1 and the significant commercial opportunity that adult Acute Lymphoblastic Leukemia represents. Furthermore, we are committed to building additional...

Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich’s ataxia (FA) patientsPlacebo-controlled Phase 1 trials in FA patients remain on track for topline data in Q2 2021Cash and investments of $92.6 million as of December 31, 2020BALA CYNWYD, Pa., March 04, 2021 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2020 operating and financial results.“2020 was a transformational year for Larimar as we entered the public market, built a strong institutional shareholder base, and reported initial clinical findings in our lead...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 04, 2021 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage biopharmaceutical company, today reports its audited financial results for the year ended December 31, 2020 and provides updates on key clinical and commercial developments.   The Company also intends to seek shareholders’ approval to change its name to HUTCHMED (China) Limited at its forthcoming Annual General Meeting. For more information on the new corporate name, see 2020 Full Year Results & Business Updates—VI. Evolution of Our Corporate Identity.2020 FULL YEAR RESULTS & BUSINESS UPDATES“At the heart of HUTCHMED lies a prolific in-house novel drug discovery and development engine that has produced ten clinical-stage drug candidates...